These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 21552988)

  • 1. The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan.
    Oze T; Hiramatsu N; Yakushijin T; Mochizuki K; Imanaka K; Yamada A; Oshita M; Kaneko A; Hagiwara H; Mita E; Ito T; Nagase T; Inui Y; Hijioka T; Tamura S; Yoshihara H; Hayashi E; Imai Y; Kato M; Hosui A; Miyagi T; Yoshida Y; Ishida H; Tatsumi T; Kiso S; Kanto T; Kasahara A; Takehara T; Hayashi N
    J Gastroenterol; 2011 Jul; 46(7):944-52. PubMed ID: 21552988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan.
    Oze T; Hiramatsu N; Yakushijin T; Mochizuki K; Oshita M; Hagiwara H; Mita E; Ito T; Inui Y; Fukui H; Hijioka T; Katayama K; Tamura S; Yoshihara H; Inoue A; Imai Y; Hayashi E; Kato M; Hosui A; Miyagi T; Ishida H; Yoshida Y; Tatsumi T; Kiso S; Kanto T; Kasahara A; Takehara T; Hayashi N
    J Gastroenterol; 2011 Aug; 46(8):1031-7. PubMed ID: 21538029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
    Gonçales FL; Moma CA; Vigani AG; Angerami AF; Gonçales ES; Tozzo R; Pavan MH; Gonçales NS
    BMC Infect Dis; 2010 Jul; 10():212. PubMed ID: 20646277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.
    Yamada G; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
    Clin Drug Investig; 2008; 28(1):9-16. PubMed ID: 18081356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term pegylated interferon monotherapy following 72 weeks of pegylated interferon and ribavirin in hepatitis C virus genotype-1-infected slow responders.
    Watanabe S; Kobayashi Y; Kawata K; Noritake H; Chida T; Nagasawa M; Kageyama F; Kawamura K; Sasada Y; Suda T
    Intern Med; 2015; 54(3):273-9. PubMed ID: 25748735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of pegylated interferon plus ribavirin combination therapy for hepatitis C patients with normal ALT levels: a matched case-control study.
    Hiramatsu N; Inoue Y; Oze T; Kurashige N; Yakushijin T; Mochizuki K; Miyagi T; Tatsumi T; Kiso S; Kanto T; Kasahara A; Takehara T; Oshita M; Mita E; Hagiwara H; Inui Y; Katayama K; Tamura S; Yoshihara H; Imai Y; Hayashi N
    J Gastroenterol; 2011 Nov; 46(11):1335-43. PubMed ID: 21858637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reducing Peg-IFN doses causes later virologic response or no response in HCV genotype 1 patients treated with Peg-IFN alfa-2b plus ribavirin.
    Oze T; Hiramatsu N; Song C; Yakushijin T; Iio S; Doi Y; Oshita M; Hagiwara H; Mita E; Ito T; Inui Y; Hijioka T; Tamura S; Yoshihara H; Inoue A; Imai Y; Hayashi E; Kato M; Miyazaki M; Hosui A; Miyagi T; Yoshida Y; Tatsumi T; Kiso S; Kanto T; Kasahara A; Hayashi N; Takehara T
    J Gastroenterol; 2012 Mar; 47(3):334-42. PubMed ID: 22109353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy.
    Derbala MF; El Dweik NZ; Al Kaabi SR; Al-Marri AD; Pasic F; Bener AB; Shebl FM; Amer AM; Butt MT; Yakoob R; John A; Al Mohanadi M; Al Khinji MA
    J Viral Hepat; 2008 Aug; 15(8):591-9. PubMed ID: 18482284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective prediction of outcome of combination therapy with pegylated interferon alpha 2b plus ribavirin in Japanese patients with genotype-1 chronic hepatitis C using early viral kinetics and new indices.
    Nomura H; Miyagi Y; Tanimoto H; Higashi M; Ishibashi H
    J Gastroenterol; 2009; 44(4):338-45. PubMed ID: 19277449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial.
    Liu CH; Liu CJ; Lin CL; Liang CC; Hsu SJ; Yang SS; Hsu CS; Tseng TC; Wang CC; Lai MY; Chen JH; Chen PJ; Chen DS; Kao JH
    Clin Infect Dis; 2008 Nov; 47(10):1260-9. PubMed ID: 18834319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy of pegylated interferon alpha-2a and ribavirin treatment in chronic hepatitis C patients depends on various baseline parameters and early viral kinetics].
    Husa P; Slesinger P; Stroblová H; Svobodník A; Husová L
    Klin Mikrobiol Infekc Lek; 2008 Apr; 14(2):67-73. PubMed ID: 18756436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin.
    Martinot-Peignoux M; Stern C; Maylin S; Ripault MP; Boyer N; Leclere L; Castelnau C; Giuily N; El Ray A; Cardoso AC; Moucari R; Asselah T; Marcellin P
    Hepatology; 2010 Apr; 51(4):1122-6. PubMed ID: 20069649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses.
    Inoue Y; Hiramatsu N; Oze T; Yakushijin T; Mochizuki K; Hagiwara H; Oshita M; Mita E; Fukui H; Inada M; Tamura S; Yoshihara H; Hayashi E; Inoue A; Imai Y; Kato M; Miyagi T; Hohsui A; Ishida H; Kiso S; Kanto T; Kasahara A; Takehara T; Hayashi N
    J Viral Hepat; 2010 May; 17(5):336-44. PubMed ID: 19678893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between inosine triphosphate genotype and outcome of extended therapy in hepatitis C virus patients with a late viral response to pegylated-interferon and ribavirin.
    Hai H; Tamori A; Enomoto M; Morikawa H; Uchida-Kobayashi S; Fujii H; Hagihara A; Kawamura E; Thuy le TT; Tanaka Y; Kawada N
    J Gastroenterol Hepatol; 2014 Jan; 29(1):201-7. PubMed ID: 23980585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin.
    Oze T; Hiramatsu N; Yakushijin T; Kurokawa M; Igura T; Mochizuki K; Imanaka K; Yamada A; Oshita M; Hagiwara H; Mita E; Ito T; Inui Y; Hijioka T; Tamura S; Yoshihara H; Hayashi E; Inoue A; Imai Y; Kato M; Yoshida Y; Tatsumi T; Ohkawa K; Kiso S; Kanto T; Kasahara A; Takehara T; Hayashi N
    J Viral Hepat; 2009 Aug; 16(8):578-85. PubMed ID: 19552663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response.
    Kamal SM; El Kamary SS; Shardell MD; Hashem M; Ahmed IN; Muhammadi M; Sayed K; Moustafa A; Hakem SA; Ibrahiem A; Moniem M; Mansour H; Abdelaziz M
    Hepatology; 2007 Dec; 46(6):1732-40. PubMed ID: 17943989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial.
    Mecenate F; Pellicelli AM; Barbaro G; Romano M; Barlattani A; Mazzoni E; Bonaventura ME; Nosotti L; Arcuri P; Picardi A; Barbarini G; D'Ambrosio C; Paffetti A; Andreoli A; Soccorsi F;
    BMC Gastroenterol; 2010 Feb; 10():21. PubMed ID: 20170514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter study to clarify the optimal HCV-RNA negative period during combined therapy with pegylated interferon plus ribavirin in patients with chronic hepatitis caused by HCV genotype 2.
    Nagoshi S; Koshima Y; Nakamura I; Funyu J; Sekine C; Harada Y; Nishikawa K; Yoshida T; Matsui A; Sotome N; Toshima K; Takegoshi S; Shiomi M; Tanaka M; Saito A; Fujiwara K; Mochida S
    Intern Med; 2012; 51(1):9-15. PubMed ID: 22214617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic effectiveness of biosimilar standard interferon versus pegylated interferon for chronic hepatitis C genotypes 2 or 3.
    Vigani AG; Gonçales ES; Pavan MH; Genari F; Tozzo R; Lazarini MS; Fais V; Feltrin A; Gonçales NS; Gonçales FL
    Braz J Infect Dis; 2012; 16(3):232-6. PubMed ID: 22729189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment efficacy of pegylated interferon plus ribavirin therapy in chronic hepatitis C patients with mixed genotype 1/2 infection.
    Huang CI; Huang CF; Huang JF; Dai CY; Yeh ML; Hsieh MY; Lin ZY; Chen SC; Wang LY; Yu ML; Chuang WL
    J Gastroenterol Hepatol; 2014 May; 29(5):1012-8. PubMed ID: 24325201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.